MX2020005348A - Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida. - Google Patents

Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.

Info

Publication number
MX2020005348A
MX2020005348A MX2020005348A MX2020005348A MX2020005348A MX 2020005348 A MX2020005348 A MX 2020005348A MX 2020005348 A MX2020005348 A MX 2020005348A MX 2020005348 A MX2020005348 A MX 2020005348A MX 2020005348 A MX2020005348 A MX 2020005348A
Authority
MX
Mexico
Prior art keywords
cyclopropylmeth
sulfonamide
quinoline
piperazine
phenyl
Prior art date
Application number
MX2020005348A
Other languages
English (en)
Inventor
Liting Guo
Mahmoud Mirmehrabi
Jacob P Sizemore
Yeqing Su
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64734113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020005348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2020005348A publication Critical patent/MX2020005348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción se proporcionan formas de sal de hemisulfato amorfas y cristalinas de la fórmula (I). Además, se proporcionan composiciones farmacéuticas que comprenden las formas de sales de hemisulfato amorfas y cristalinas, métodos para su fabricación y usos de estas para tratar afecciones asociadas con la piruvato quinasa tal como, por ejemplo, la deficiencia de piruvato quinasa.
MX2020005348A 2017-11-22 2018-11-21 Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida. MX2020005348A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US201862691709P 2018-06-29 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (1)

Publication Number Publication Date
MX2020005348A true MX2020005348A (es) 2020-08-13

Family

ID=64734113

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005348A MX2020005348A (es) 2017-11-22 2018-11-21 Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
MX2022009998A MX2022009998A (es) 2017-11-22 2020-07-13 Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009998A MX2022009998A (es) 2017-11-22 2020-07-13 Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.

Country Status (27)

Country Link
US (1) US11254652B2 (es)
EP (2) EP3713919B1 (es)
JP (2) JP7275130B2 (es)
KR (3) KR102777452B1 (es)
CN (2) CN111372920B (es)
AU (2) AU2018373122B2 (es)
BR (1) BR112020010185A2 (es)
CA (1) CA3081945A1 (es)
DK (1) DK3713919T3 (es)
ES (1) ES2959764T3 (es)
FI (1) FI3713919T3 (es)
HR (1) HRP20230931T1 (es)
HU (1) HUE063264T2 (es)
IL (3) IL305343B2 (es)
LT (1) LT3713919T (es)
MD (1) MD3713919T2 (es)
MX (2) MX2020005348A (es)
PH (1) PH12020550644A1 (es)
PL (1) PL3713919T3 (es)
PT (1) PT3713919T (es)
RS (1) RS64592B1 (es)
SG (1) SG11202004587XA (es)
SI (1) SI3713919T1 (es)
SM (1) SMT202300327T1 (es)
TW (1) TWI808108B (es)
UA (1) UA127502C2 (es)
WO (1) WO2019104134A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561132C2 (ru) * 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US20230192618A1 (en) * 2019-05-22 2023-06-22 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
US11878049B1 (en) * 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2021154987A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mitapivat and process for preparation thereof
CN116568281A (zh) * 2020-09-25 2023-08-08 安吉奥斯医药品有限公司 药物制剂
EP4216956A1 (en) * 2020-09-25 2023-08-02 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023154036A1 (en) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
KR20240004620A (ko) * 2021-04-30 2024-01-11 아지오스 파마슈티컬스 아이엔씨. 미타피바트를 적정하는 방법
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
WO2023091414A1 (en) 2021-11-16 2023-05-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
WO2024084501A1 (en) 2022-10-17 2024-04-25 Mylan Laboratories Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos
WO2024228131A1 (en) * 2023-05-02 2024-11-07 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof
WO2025008787A1 (en) * 2023-07-05 2025-01-09 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of mitapivat hemisulfate
WO2025083627A1 (en) * 2023-10-18 2025-04-24 Apitoria Pharma Private Limited Novel crystalline forms of mitapivat sulfate and processes for preparation
WO2025146636A1 (en) * 2024-01-03 2025-07-10 Tianish Laboratories Private Limited Novel crystalline polymorphs of mitapivat sulfate salt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
RU2561132C2 (ru) * 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
WO2013056153A1 (en) 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä

Also Published As

Publication number Publication date
EP4285904A3 (en) 2023-12-20
TWI808108B (zh) 2023-07-11
BR112020010185A2 (pt) 2021-01-12
EP3713919B1 (en) 2023-08-02
IL305343B2 (en) 2026-01-01
WO2019104134A1 (en) 2019-05-31
TW202334115A (zh) 2023-09-01
HUE063264T2 (hu) 2024-01-28
IL322576A (en) 2025-10-01
CA3081945A1 (en) 2019-05-31
HRP20230931T1 (hr) 2023-11-24
IL274488B2 (en) 2024-01-01
AU2018373122A1 (en) 2020-05-21
JP7275130B2 (ja) 2023-05-17
UA127502C2 (uk) 2023-09-13
US11254652B2 (en) 2022-02-22
SI3713919T1 (sl) 2023-10-30
PL3713919T3 (pl) 2023-12-27
AU2018373122B2 (en) 2023-11-09
US20200277279A1 (en) 2020-09-03
SG11202004587XA (en) 2020-06-29
FI3713919T3 (fi) 2023-09-29
RS64592B1 (sr) 2023-10-31
CN117551030A (zh) 2024-02-13
KR20240108581A (ko) 2024-07-09
MX2022009998A (es) 2022-09-19
PT3713919T (pt) 2023-10-26
DK3713919T3 (da) 2023-09-25
CN111372920B (zh) 2023-10-20
LT3713919T (lt) 2023-10-10
EP4285904A2 (en) 2023-12-06
IL305343A (en) 2023-10-01
ES2959764T3 (es) 2024-02-28
US20220220093A1 (en) 2022-07-14
JP2023093762A (ja) 2023-07-04
KR20250034202A (ko) 2025-03-10
KR102682430B1 (ko) 2024-07-08
AU2024200724A1 (en) 2024-02-22
IL274488B1 (en) 2023-09-01
AU2024200724B2 (en) 2026-02-05
IL305343B1 (en) 2025-09-01
SMT202300327T1 (it) 2023-11-13
MD3713919T2 (ro) 2024-02-29
TW201930289A (zh) 2019-08-01
KR102777452B1 (ko) 2025-03-10
JP2021504338A (ja) 2021-02-15
EP3713919A1 (en) 2020-09-30
CN111372920A (zh) 2020-07-03
IL274488A (en) 2020-06-30
PH12020550644A1 (en) 2021-04-26
KR20200090787A (ko) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2020005348A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CL2017003245A1 (es) Derivados de piperidina 1,4-sustituidos
CL2017002650A1 (es) Compuestos novedosos
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2017000541A1 (es) Compuestos y composiciones como inhibidores de raf kinasa
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
CO2017001884A2 (es) Polimorfos de selinexor
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CR20120328A (es) Compuestos antiparasitarios de dihidroazol y composiciones que comprenden a los mismos
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
PY1520796A (es) Composiciones plaguicidas y metodos relacionados
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso